Primary immunodeficiency syndrome

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 2
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Immunoglobulin 1 substance
Unknown / small molecule 1 substance
Phase III: 2 Phase II/III: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Octapharma Pharmazeutika Produktionsgesellschaft mbH Commercial
    HUMAN NORMAL IMMUNOGLOBULIN
    2024-511231-94-00 5 countries 2021 n=50
    Ended
  • Takeda Development Center Americas Inc. Commercial
    HUMAN NORMAL IMMUNOGLOBULIN, HYALURONIDASE (HUMAN RECOMBINANT)
    2023-505946-24-00 8 countries 2025 n=17
    Recruiting

Phase II/III

1 trial
  • Takeda Development Center Americas Inc. Commercial
    HUMAN NORMAL IMMUNOGLOBULIN; HUMAN NORMAL IMMUNOGLOBULIN, HYALURONIDASE (HUMAN RECOMBINANT)
    2022-502095-23-01 8 countries 2024 n=27
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Takeda Development Center Americas Inc. Commercial 2 Phase II/III, Phase III 1
Octapharma Pharmazeutika Produktionsgesellschaft mbH Commercial 1 Phase III 0
New trials by year
2021
1
2024
1
2025
1
← All indication landscapes